Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiovascular drug-drug interactions.

J R Anderson1, J J Nawarskas

  • 1University of New Mexico, College of Pharmacy, Albuquerque, New Mexico, USA.

Cardiology Clinics
|June 16, 2001
PubMed
Summary

Understanding drug-drug interactions is crucial for cardiovascular disease patients. Clinicians can minimize risks by knowing drug interactions and basic pharmacokinetic principles.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bivalirudin: a new approach to anticoagulation.

Heart disease (Hagerstown, Md.)·2002
Same author

Ranolazine: a potential new treatment for chronic stable angina.

Heart disease (Hagerstown, Md.)·2002
Same author

Omapatrilat: a unique new agent for the treatment of cardiovascular disease.

Heart disease (Hagerstown, Md.)·2001
Same author

Acadesine: a unique cardioprotective agent for myocardial ischemia.

Heart disease (Hagerstown, Md.)·2001
Same author

Vitamin C in the prevention of nitrate tolerance.

The Annals of pharmacotherapy·2000
Same author

Update on the interaction between aspirin and angiotensin-converting enzyme inhibitors.

Pharmacotherapy·2000

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Clinical Pharmacy

Background:

  • Drug-drug interactions (DDIs) pose significant clinical challenges, particularly for patients with cardiovascular disease.
  • Predicting DDIs is complex due to interpatient variability in drug metabolism and disposition.
  • Despite challenges, some DDIs can be anticipated and managed with clinical expertise.

Purpose of the Study:

  • To highlight the clinical relevance of documented and suspected drug-drug interactions in cardiovascular disease management.
  • To emphasize the importance of clinician knowledge in mitigating adverse drug events.
  • To provide a foundation for understanding and managing DDIs.

Main Methods:

  • Review of documented and suspected drug-drug interactions relevant to cardiovascular patients.
  • Discussion of pharmacokinetic and pharmacodynamic principles influencing drug interactions.
  • Emphasis on clinical judgment and knowledge-based avoidance strategies.

Main Results:

  • Drug-drug interactions are common and clinically relevant in cardiovascular patient care.
  • Interpatient variability complicates the prediction of drug interactions.
  • Knowledge of drug interactions and pharmacokinetic/pharmacodynamic principles aids in risk management.

Conclusions:

  • Clinicians must maintain current knowledge of drug-drug interactions affecting cardiovascular patients.
  • Understanding pharmacokinetic and pharmacodynamic principles is essential for predicting and minimizing DDIs.
  • Proactive management through clinical judgment can reduce the incidence and severity of DDIs in cardiovascular medicine.

Related Experiment Videos